Kindeva Drug Delivery acquires Summit Biosciences
Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer
Biocon, an India-based biopharmaceutical company, has entered into an exclusive licensing and supply agreement with Brazilian specialty pharmaceutical company Biomm for the commercialisation of Semaglutide (gOzempic), a drug used to improve glycemic control in adults with type-2 diabetes.